

**Table S1.** COVID-19 complete vaccination schedule effectiveness for all age groups in solid-organ transplant recipients in Colombia, by scheme. ESPERANZA cohort

COVID-19 complete schedule effectiveness						
Vaccination	Infection		Hospitalization		Death	
schedule type	% (CI95%)	p-value	%(CI95%)	p-value	%(CI95%)	p-value
Homologous	72.5 (67.8-	<0.001	83.1 (77.8-87.2)	<0.001	91.8 (88.3-94.3)	<0.001
schedule	76.4)					
	73.4 (68.6-	<0.001	85.4 (80.1-89.3)	<0.001	93.4 (89.8-95.7)	<0.001
Pfizer	77.5)					
	74.2 (68.3-	<0.001	83.3 (75.3-88.7)	<0.001	92.6 (87.5-95.6)	<0.001
Sinovac	79.1)					
	73.7 (65.2-	<0.001	88.4 (77.4-94.0)	<0.001	97.1 (87.9-99.3)	<0.001
Janssen	80.1)					
	28.1 (0-48.9)	0.059	85.2 (64.6-93.8)	<0.001	96.9 (76.5-99.6)	<0.001
Moderna						
	67.9 (57.9-	<0.001	82.5 (70.9-89.5)	<0.001	93.8 (86.4-97.1)	<0.001
Astrazeneca	75.5)					
Heterologous	73.6 (0-93.5)	0.064	--	--	--	--
schedule						

Estimates adjusted for age (y); sex, affiliation regime; municipality of residence; presence of comorbidities (CKD, cancer, DM, HBP and HIV infection); and prevalent variant at the time of infection. Unvaccinated individuals were the reference group in all models.-- Nonestimable effectiveness due to a low sample size ( $n < 200$ )

**Table S2.** COVID-19 vaccine booster effectiveness for all age groups in solid-organ transplant recipients in Colombia, by scheme. ESPERANZA cohort

COVID-19 vaccine booster effectiveness						
Vaccine booster type	Infection		Hospitalization		Death	
	% (CI95%)	p-value	% (CI95%)	p-value	% (CI95%)	p-value
Homologous schedule	69.8 (59.2-77.6)	< 0.001	81.0 (66.9-89.1)	< 0.001	91.7 (82.4-96.1)	< 0.001
Pfizer	72.5 (59.5-81.4)	< 0.001	82.9 (63.5-92.1)	< 0.001	89.8 (73.7-96.1)	< 0.001
Sinovac	58.1 (35.9-72.7)	< 0.001	67.9 (35.1-84.2)	0.001	91.9 (76.2-97.2)	< 0.001
Janssen	80.7 (0-97.3)	0.104	--	--	--	--
Moderna	--	--	--	--	--	--
Astrazeneca	76.2 (50.5-88.5)	< 0.001	--	--	--	--
Heterologous schedule	76.4 (68.1-82.5)	< 0.001	92.3 (83.7-96.4)	< 0.001	95.6 (88.6-98.3)	< 0.001
Pfizer + Moderna	75.1 (61.2-83.9)	< 0.001	91.6 (72.8-97.4)	< 0.001	97.3 (80.5-99.6)	< 0.001
Sinovac + Pfizer	70.2 (37.6-85.8)	0.0013	90.8 (31.9-98.8)	0.0194	--	--
Pfizer + AstraZeneca	80.1 (63.7-89.1)	< 0.001	95.3 (65.7-99.4)	0.0025	93.4 (51.3-99.1)	0.0076

Estimates adjusted for age (years); sex, affiliation regime; municipality of residence; presence of comorbidities (CKD, cancer, DM, HBP and HIV infection); and prevalent variant at the time of infection. Unvaccinated individuals were the reference group in all models.

-- Non-estimable effectiveness due to a low sample size ( $n < 200$ )